Page last updated: 2024-08-23

pravastatin and thrombin receptor peptide (42-55)

pravastatin has been researched along with thrombin receptor peptide (42-55) in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Elisaf, M; Goudevenos, JA; Mitsios, JV; Papathanasiou, AI; Rodis, FI; Tselepis, AD	1

Trials

1 trial(s) available for pravastatin and thrombin receptor peptide (42-55)

Article	Year
Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes. Circulation, 2004, Mar-23, Volume: 109, Issue:11 Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; CD40 Ligand; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inactivation, Metabolic; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Stents; Ticlopidine; Treatment Outcome	2004

Article

Year

Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.

Circulation, 2004, Mar-23, Volume: 109, Issue:11

Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Atorvastatin; CD40 Ligand; Clopidogrel; Combined Modality Therapy; Coronary Disease; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inactivation, Metabolic; Male; Middle Aged; P-Selectin; Peptide Fragments; Platelet Aggregation; Platelet Aggregation Inhibitors; Pravastatin; Pyrroles; Stents; Ticlopidine; Treatment Outcome

2004